Chaewon Hwang, PGY-5 and Co-Chief Resident in Radiation Oncology at Tufts Medical Center, shared on X:
“Our real-world analysis showed median time to consolidative immunotherapy of 84 days from CRT start (~42days post-CRT completion) in Stage III NSCLC (2018-2021). Uninsured, Medicaid, and tx at non-academic independently associated w/ longer time to intiation.”
This also can be interesting:
LIGHT-NING: Real-World Nivolumab Plus Ipilimumab Shows Durable Outcomes in Metastatic NSCLC
